{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-23-000028","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.934571+00:00","generated_at":"2026-06-15T22:17:05.369726+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Keros Q1 net loss $35.8M, cash $351.4M; KER-012 Phase 2 starts H1 2023","bullets":["Net loss of $35.8M vs $24.2M in Q1 2022; R&D spend $31.1M (+$13.0M YoY) driving pipeline.","Cash and equivalents $351.4M as of March 31, 2023; runway into Q4 2025.","Dr. Alpna Seth appointed to board of directors in May 2023.","KER-012 Phase 2 trial for pulmonary arterial hypertension planned to start H1 2023.","KER-050 Phase 2 data readouts in MDS and myelofibrosis expected later this year."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-23-000028","json":"https://secwatch.observer/filing/0001664710-23-000028.json","markdown":"https://secwatch.observer/filing/0001664710-23-000028.md","text":"https://secwatch.observer/filing/0001664710-23-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471023000028/0001664710-23-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471023000028/kros-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:17:05.369726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e785718fcecdbfab3fbfc7e8db1b3bd485e09143","claim":"Keros Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income net loss of $35.8 million.","evidence_excerpt":"Keros reported a net loss of $35.8 million in the first quarter of 2023 as compared to a net loss of $24.2 million in the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471023000028/0001664710-23-000028-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"net loss of $35.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}